Azd4604 placebo
Sponsors
Astrazeneca AB, AstraZeneca AB
Conditions
Adult Patients with Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABAAsthma
Phase 2
A Phase 2a Randomised, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of AZD4604 Twice Daily for Twelve Weeks in Adult Patients with Moderate to Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA
CompletedCTIS2023-506000-50-00
Start: 2024-09-26End: 2025-06-12Target: 124Updated: 2025-06-04
A Randomised, Double-blind, Parallel Group, Placebo Controlled,
4-Week, Phase II Study to Evaluate the Effect of AZD4604 on
Airway Inflammation and Biomarkers in Adults with Asthma - Artemisia study
CompletedCTIS2023-510291-32-00
Start: 2024-09-26End: 2025-08-13Target: 20Updated: 2025-07-02